[1] SHUNSUKE TAWARA Hiroaki S. Progress of the study of rho-kinase and future perspective of the inhibitor.[J]. Yakugaku zasshi?: Journal of the Pharmaceutical Society of Japan, 2007, 127 3: 501-514. DOI:
10.1248/yakushi.127.501[2] S. DAVIES. Specificity and mechanism of action of some commonly used protein kinase inhibitors.[J]. The Ukrainian Biochemical Journal, 2000, 24 1: 95-105. DOI:
10.1042/bj3510095[3] MASAHIKO OKA. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.[J]. Circulation research, 2007, 100 6: 923-929. DOI:
10.1161/01.res.0000261658.12024.18[4] LIMEI YIN. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.[J]. Molecular Cancer Therapeutics, 2007, 6 5: 1517-1525. DOI:
10.1158/1535-7163.mct-06-0689[5] YUICHI KIKUCHI. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.[J]. Journal of Endocrinology, 2007, 192 3: 595-603. DOI:
10.1677/joe-06-0045